Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immune modulation therapy - Celldex Therapeutics

Drug Profile

Research programme: immune modulation therapy - Celldex Therapeutics

Alternative Names: CDX-527; LOR-A04; LOR-S01; LOR-S03

Latest Information Update: 20 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lorantis
  • Developer Celldex Therapeutics Inc; Lorantis
  • Class Bispecific antibodies; DNA; Proteins
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Allergic asthma; Immunological disorders; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection; Viral infections

Most Recent Events

  • 01 Apr 2019 Celldex Therapeutics plans clinical studies for Cancer
  • 29 Mar 2019 Pharmacodynamics data from in-vitro studies presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
  • 21 Apr 2018 Preclinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top